

Special Issue

Emerging Issues in COVID and T Cells

Message from the Guest Editor

As variants such as Omicron evolve to avoid antibodies, the role of another part of the immune system, T cells, seems to become more prominent. In this research topic, we would like to include recent scientific developments on the role of T cells in SARS-CoV-2 infection and immune response post vaccination. We cordially invite authors to contribute original research articles or reviews focusing on, but not limited to, the following:

- Functional characterization of SARS-CoV-2 T-cell response to infection and vaccination.
- Phenotypic characteristic of T-cell subpopulations during SARS-CoV-2 infection and/or post-vaccination.
- Mechanisms regulating infection/vaccine-induced T-cell longevity.
- Characterization of immune memory induced by SARS-CoV-2 infections and vaccines.
- Cross-talk between T cells and other immune system components in infection or vaccination.
- Factors that influence T-cell responses (immunizing; immunosenescence; malignancy onset; or the influence of associated immunotherapies, drugs, or immunosuppression).
- Role of TCRs and HLA in T-cell response to SARS-CoV-2 infection or vaccines.

Guest Editor

Dr. Emilia Jaskuła

1. L. Hirschfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland
2. Lower Silesian Oncology, Pulmonology, and Hematology Center, Wrocław, Poland

Deadline for manuscript submissions

closed (29 February 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/115816

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).